Keyword: European Society for Medical Oncology
Here's a finding to incorporate into the pricing debate: New cancer meds often add little benefit for patients, but carry significantly higher prices.
BMS’s Opdivo failed a key small cell lung cancer trial in October, but the results may still be enough to protect the approval it already has.
Despite a field that features four entrants and a wealth of data supporting their use, some doctors still aren't on board with PARP inhibitors.
As the European Society for Medical Oncology meeting comes to a close, one thing is clear: ESMO isn’t the meeting it used to be.
BMS is looking to push its Opdivo-Yervoy combo further into colorectal cancer, and with new phase 2 data, it just might be able to.
AZ and Merck's Lynparza has posted data in BRCA-mutated patients who've just wrapped up an initial round of chemo. And it’s entering with a bang.
Pfizer has long been kidney cancer player, but it’s looking to take things up a notch with its latest immunotherapy data.
Roche’s Tecentriq is gunning for a first-in-class triple-negative breast cancer nod, and it’s out with data that could help it get the job done.
Pfizer’s Ibrance failed to prove it could help some patients live longer, but executives say those study results still make a “compelling” case.
As a big ESMO 2018 kicks off, here are the studies we're most excited to see.